trending Market Intelligence /marketintelligence/en/news-insights/trending/g7gn7dzuxix9y9-n59uvja2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

South Korean Multichannel Industry To Survive With Right Strategies

South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities

Mining Exploration Insights: Financing Falls To 8-Month Low In October

Taking Advantage of Issuance Trends in 2020

Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

Xbrane Biopharma AB (publ) signed a distribution agreement with BioAvenir for marketing and sales of Spherotide in Israel.

Xbrane will receive 1 million Swedish kronor as a license fee, divided into up-front and milestone payments until product launch. Both companies will share the profits from the sales of the drug in Israel, where it is expected to launch in 2020.

The drug's launch in Israel is subject to market authorization from Israel's Ministry of Health.

Spherotide is used primarily in the treatment of prostate cancer, endometriosis and uterine fibroids. For the Israeli market, it will be produced in Xbrane's production facility in Italy for resale to BioAvenir.

Xbrane estimates, based on expected price and penetration, that Spherotide has a sales potential of about 5 million Swedish kronor annually in Israel.

BioAvenir is a privately held company specializing in licensing, registering, and commercializing pharmaceuticals and special products in Israel.

As of Dec. 20, US$1 was equivalent to 9.37 Swedish kroner.